

14. Hörz S, Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G. Ten-year use of mental health services by patients with borderline personality disorder and with other axis II disorders. *Psychiatr Serv* 2010;61:612-6. <http://dx.doi.org/10.1176/ps.2010.61.6.612>
15. Andrews G, Titov N. Changing the face of mental health care through needs-based planning. *Aust Health Rev* 2007;31 Suppl 1:S122-8. <http://dx.doi.org/10.1071/AH07S122>
16. National Health and Medical Research Council. Clinical Practice Guideline for the Management of Borderline Personality Disorder. Melbourne: National Health and Medical Research Council; 2012.
17. Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline personality disorder. *Lancet* 2011;377:74-84. [http://dx.doi.org/10.1016/S0140-6736\(10\)61422-5](http://dx.doi.org/10.1016/S0140-6736(10)61422-5)
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013.
19. Zimmerman M, Chelminski I, Young D, Dalrymple K, Martinez J. Does the presence of one feature of borderline personality disorder have clinical significance? Implications for dimensional ratings of personality disorders. *J Clin Psychiatry* 2012;73:8-12. <http://dx.doi.org/10.4088/JCP.10m06784>
20. Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorder. *Lancet* 2015;385:717-26. [http://dx.doi.org/10.1016/S0140-6736\(14\)61995-4](http://dx.doi.org/10.1016/S0140-6736(14)61995-4)
21. Chanan AM. Borderline personality disorder in young people: are we there yet? *J Clin Psychol* 2015;71:778-91. <http://dx.doi.org/10.1002/jclp.22205>
22. Crawford TN, Cohen P, First MB, Skodol AE, Johnson JG, Kasen S. Comorbid Axis I and Axis II disorders in early adolescence: outcomes 20 years later. *Arch Gen Psychiatry* 2008;65:641-8. <http://dx.doi.org/10.1001/archpsyc.65.6.641>
23. Cohen P, Crawford TN, Johnson JG, Kasen S. The children in the community study of developmental course of personality disorder. *J Pers Disord* 2005;19:466-86. <http://dx.doi.org/10.1521/pedi.2005.19.5.466>
24. Stoffers JM, Völlm BA, Rucker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline personality disorder. *Cochrane Database Syst Rev* 2012;8:CD005652.
25. Bateman AW, Gunderson J, Mulder R. Treatment of personality disorder. *Lancet* 2015;385:735-43. [http://dx.doi.org/10.1016/S0140-6736\(14\)61394-5](http://dx.doi.org/10.1016/S0140-6736(14)61394-5)
26. De Panfilis C, Marchesi C, Cabrino C, Monici A, Politi V, Rossi M, et al. Patient factors predicting early dropout from psychiatric outpatient care for borderline personality disorder. *Psychiatry Res* 2012;200:422-9. <http://dx.doi.org/10.1016/j.psychres.2012.03.016>
27. Stoffers J, Völlm BA, Rucker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. *Cochrane Database Syst Rev* 2010;6:CD005653.
28. National Collaborating Centre for Mental Health. Borderline personality disorder: treatment and management. Report No.: CG78. London: National Institute for Health and Clinical Excellence; 2009.
29. Stoffers JM, Lieb K. Pharmacotherapy for borderline personality disorder--current evidence and recent trends. *Curr Psychiatry Rep* 2015;17:534. <http://dx.doi.org/10.1007/s11920-014-0534-0>
30. Lieb K, Völlm B, Rucker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. *Br J Psychiatry* 2010;196:4-12. <http://dx.doi.org/10.1192/bjp.bp.108.062984>
31. Tyrer P, Silk KR. A comparison of UK and US guidelines for drug treatment in borderline personality disorder. *Int Rev Psychiatry* 2011;23:388-94. <http://dx.doi.org/10.3109/09540261.2011.606540>
32. Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. *J Clin Psychiatry* 2004;65:28-36. <http://dx.doi.org/10.4088/JCP.v65n0105>

Book review

Handbook of drug administration via enteral feeding tubes. 3rd ed.

White R, Bradnam V

London: Pharmaceutical Press; 2015.

732 pages

This new edition covers over 400 drugs and includes 29 new monographs. It aims to support safe and effective prescribing by providing practical recommendations on the administration of drugs via enteral tubes. Information in the book comes from pharmaceutical companies, published information (which is limited), and research undertaken largely by pharmacists.

The introductory chapters cover technical and pharmaceutical issues with tubes, drugs and administration, as well as tube blockage, drug errors and occupational exposure.

The monographs list UK formulations and relevant data for each drug. Information is provided on sites of oral absorption, alternative routes, interactions with food and enteral feeds, health and safety precautions, altering available products, and intragastric and intrajejunal administration procedures.

The products listed may differ from those available in Australia. The print is very small, and the book does not cover administration to patients with swallowing difficulties. A publication by the Society of Hospital Pharmacists of Australia, the Australian Don't Rush to Crush Handbook, covers administration via enteral tubes in less detail, but includes information on swallowing difficulty and products available in Australia. There is some overlap between the two books, but each contains unique content.

This is a practical book which contains more detail on drug administration via enteral tubes than is readily available elsewhere. Because such administration is generally 'off-label' (outside the approved product information), those prescribing, dispensing or administering drugs via enteral tubes may be liable if the patient experiences adverse effects due to the route or alteration of the product. This makes reliable information on the topic particularly valuable. The handbook would be useful to nurses, pharmacists, doctors and dietitians who regularly deal with patients on enteral feeds.

Leone Snowden

Specialist pharmacist
NSW Medicines Information
Centre
Sydney

Aust Prescr 2016;39:53

<http://dx.doi.org/10.18773/austprescr.2016.004>

